Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Decreases By 5.0%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 47,200 shares, a drop of 5.0% from the July 31st total of 49,700 shares. Approximately 3.6% of the company’s stock are short sold. Based on an average daily trading volume, of 45,300 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Trading of Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC bought a new stake in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned about 7.97% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by institutional investors and hedge funds.

Avenue Therapeutics Trading Up 9.8 %

NASDAQ ATXI opened at $2.79 on Wednesday. The business has a fifty day simple moving average of $2.99 and a 200 day simple moving average of $6.09. Avenue Therapeutics has a 12 month low of $2.25 and a 12 month high of $64.27. The firm has a market capitalization of $3.99 million, a P/E ratio of -0.35 and a beta of -0.19.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Friday, August 9th. The company reported ($6.43) EPS for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.